Albena Todorova

Albena Todorova

Auto-generated profile, based on publicly available information

Albena Todorova

Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Genetic Medico-Diagnostic Laboratory Genica, Sofia, Bulgaria, Bulgaria

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2007 in neurogenetics
Verified
Journal Article
Closed access
PDF file
ATAlbena Todorova
Albena Todorova
BGBilyana Georgieva
Bilyana Georgieva
ITIvailo Tournev
Ivailo Tournev
TTTihomir Todorov
Tihomir Todorov
NBNadja Bogdanova
Nadja Bogdanova
JHJürgen Horst
Jürgen Horst

1 June 2012 in Pediatric Neurology
Verified
Journal Article
Closed access
PDPetia Stefanova Dimova
Petia Stefanova Dimova
AKAndrey Kirov
Andrey Kirov
ATAlbena Todorova
Albena Todorova
TTTihomir Todorov
Tihomir Todorov
VMVanyo Mitev
Vanyo Mitev

1 August 2008 in Neuromuscular Disorders
Verified
Journal Article
Closed access
ATAlbena Todorova
Albena Todorova
TTTihomir Todorov
Tihomir Todorov
BGBilyana Georgieva
Bilyana Georgieva
MLMichaela Lukova
Michaela Lukova
VGVelina Guergueltcheva
Velina Guergueltcheva
VMVanyo Mitev
Vanyo Mitev

1 March 2010 in Literacy Information and Computer Education Journal
Verified
Journal Article
Open access
ATAlbena Todorova
Albena Todorova
TOThomas Osburg
Thomas Osburg

9 December 2019 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
PDF file
Radislav NakovRadislav Nakov
Radislav Nakov
SSStayko Sarafov
Stayko Sarafov
VNVentsislav Nakov
Ventsislav Nakov
MGMariana Gospodinova
Mariana Gospodinova
TTTihomir Todorov
Tihomir Todorov
ITIvailo Tournev
Ivailo Tournev
Aims: In the current study we aimed to explore the prevalence of gastrointestinal (GI) manifestations in hereditary transthyretin amyloid (hATTR) amyloidosis associated with Glu89Gln mutation. Methods: We recruited 78 patients with hATTR amyloidosis associated with Glu89Gln mutation. The diagnosis of hATTR was defined by a documented transthyretin mutation through DNA analysis. Symptoms were recorded as present or absent at the time of enrollment into the study. The gastrointestinal (GI) symptoms checklist included the following items: early satiety, nausea, vomiting, constipation, alternating diarrhea/ constipation, diarrhea, fecal incontinence and unintentional weight loss. Results: Forty-two patients (53.8%) reported at least one GI symptom or sign. Diarrhea was the most frequently reported (30.8%), followed by unintentional weight loss (28.2%) and nausea (21.8%). Fecal incontinence (3.8%) was the least common one. No significant gender related difference in overall GI symptom prevalence was found (females 52.16%, males 55%, p = 0.834). Type of disease onset was not related to GI prevalence (earlyonset 50%, late-onset 55.6%, p=0.650). After dividing the patients into groups with a disease duration of 10 years, respectively, the prevalence of GI symptoms was found to be significantly higher in later stages (26.3% vs. 55.0% vs. 78.9%, p = 0.005; OR 2.450, 95% CI 1.084-5.538). Gastrointestinal manifestations had no impact on survival (p=0.193). Conclusions: Gastrointestinal manifestations are very common in hATTR patients with Glu89Gln mutation and increase with disease duration. They are not associated with gender and onset of the disease and have no impact on patient survival. These results highlight the importance of a thorough evaluation of the GI function in patients with ATTR amyloidosis and should stimulate further studies on the phenotypic differences related to genotype and geographic origin.

1 July 2019 in Gene
Verified
Journal Article
Closed access
IYIglika Yordanova
Iglika Yordanova
ZPZornitza Pavlova
Zornitza Pavlova
AKAndrey Kirov
Andrey Kirov
TTTihomir Todorov
Tihomir Todorov
AAAssen Alexiev
Assen Alexiev
ATAlbena Todorova
Albena Todorova